Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Investigator Initiated Clinical Study of Tumor Neoantigen-pulsed Autologous Dendritic Cell Injection (YS247) in the Treatment of Patients With HRD-negative Epithelial Ovarian Cancer

NCT07455071 is registered in ClinicalTrials.gov with Peking University Third Hospital as lead sponsor.

NCT NCT07455071
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07455071 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Investigator Initiated Clinical Study of Tumor Neoantigen-pulsed Autologous Dendritic Cell Injection (YS247) in the Treatment of Patients With HRD-negative Epithelial Ovarian Cancer
Lead sponsor
Peking University Third Hospital
Phase
Not applicable
Overall status
Not yet recruiting
Start date
March 1, 2026
Completion date
November 30, 2027
Enrollment
9 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

hrd-negative epithelial ovarian cancer